Candriam SCA’s Protagonist Therapeutics PTGX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q4 | – | Sell |
-162,492
| Closed | -$7.31M | – | 705 |
|
|
2024
Q3 | $7.31M | Sell |
162,492
-111,326
| -41% | -$5.01M | 0.04% | 304 |
|
|
2024
Q2 | $9.49M | Sell |
273,818
-86,182
| -24% | -$2.99M | 0.06% | 258 |
|
|
2024
Q1 | $10.4M | Sell |
360,000
-177,000
| -33% | -$5.12M | 0.07% | 250 |
|
|
2023
Q4 | $12.3M | Sell |
537,000
-93,000
| -15% | -$2.13M | 0.09% | 227 |
|
|
2023
Q3 | $10.5M | Sell |
630,000
-95,000
| -13% | -$1.58M | 0.07% | 226 |
|
|
2023
Q2 | $20M | Buy |
725,000
+100,000
| +16% | +$2.76M | 0.14% | 157 |
|
|
2023
Q1 | $13.2M | Buy |
+625,000
| New | +$13.2M | 0.09% | 219 |
|
|
2022
Q2 | – | Sell |
-83,646
| Closed | -$1.98M | – | 813 |
|
|
2022
Q1 | $1.98M | Hold |
83,646
| – | – | 0.01% | 543 |
|
|
2021
Q4 | $2.86M | Hold |
83,646
| – | – | 0.02% | 474 |
|
|
2021
Q3 | $1.48M | Hold |
83,646
| – | – | 0.01% | 629 |
|
|
2021
Q2 | $3.75M | Buy |
+83,646
| New | +$3.75M | 0.03% | 461 |
|